Is Adaptimmune Therapeutics PLC (ADAP) A Good Stock To Buy?

Seeing as Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADP) has experienced bearish sentiment from the aggregate hedge fund industry, logic holds that there lies a certain “tier” of money managers that elected to cut their positions entirely last quarter. It’s worth mentioning that James A. Silverman’s Opaleye Management cashed in the largest investment of the “upper crust” of funds watched by Insider Monkey, totaling an estimated $0.3 million in stock, and Nathan Fischel’s DAFNA Capital Management was right behind this move, as the fund cut about $0.2 million worth of shares.

Let’s go over hedge fund activity in other stocks similar to Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADP). We will take a look at Daqo New Energy Corp (NYSE:DQ), New Home Company Inc (NYSE:NWHM), Great Panther Silver Ltd (USA) (NYSEAMEX:GPL), and Destination XL Group Inc (NASDAQ:DXLG). This group of stocks’ market values match ADAP’s market value.

As you can see these stocks had an average of 7 hedge funds with bullish positions and the average amount invested in these stocks was $37 million. That figure was $33 million in ADAP’s case. Destination XL Group Inc (NASDAQ:DXLG) is the most popular stock in this table. On the other hand New Home Company Inc (NYSE:NWHM) is the least popular one with only 5 bullish hedge fund positions. Compared to these stocks Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADP) is more popular among hedge funds. Considering that hedge funds are fond of this stock in relation to its market cap peers, it may be a good idea to analyze it in detail and potentially include it in your portfolio.

Disclosure: None